ArticlePharmaceuticals (Basel, Switzerland)2010
Pharmacogenetics of Anti-Diabetes Drugs.
Article in Pharmaceuticals (Basel, Switzerland), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 93 citations in OpenAlex.
- Fucoidan fromFoods (Basel, Switzerland) · 2022Article
- Characterization of Novel Dipeptidyl Peptidase-IV Inhibitory Peptides from Soft-Shelled Turtle Yolk Hydrolysate Using Orthogonal Bioassay-Guided Fractionations Coupled with In Vitro and In Silico Study.Pharmaceuticals (Basel, Switzerland) · 2020Article
- Article
- α-Amylase and α-glucosidase inhibitor effects and pancreatic response to diabetes mellitus on Wistar rats of Ephedra alata areal part decoction with immunohistochemical analyses.Environmental science and pollution research international · 2019Article
- Article
- Antidiabetic plant-derived nutraceuticals: a critical review.European journal of nutrition · 2018Review
- Genotypic and Phenotypic Factors Influencing Drug Response in Mexican Patients With Type 2 Diabetes Mellitus.Frontiers in pharmacology · 2018Article
- Pharmacogenetic studies update in type 2 diabetes mellitus.World journal of diabetes · 2016Review
- Computational Analysis of Single Nucleotide Polymorphisms Associated with Altered Drug Responsiveness in Type 2 Diabetes.International journal of molecular sciences · 2016Article
- Rutaecarpine ameliorates hyperlipidemia and hyperglycemia in fat-fed, streptozotocin-treated rats via regulating the IRS-1/PI3K/Akt and AMPK/ACC2 signaling pathways.Acta pharmacologica Sinica · 2016Article
- The role of clinical response to metformin in patients newly diagnosed with type 2 diabetes: a monotherapy study.Clinical and experimental medicine · 2015Article
- RGC32 deficiency protects against high-fat diet-induced obesity and insulin resistance in mice.The Journal of endocrinology · 2015Article
- Association of KCNJ11 (E23K) gene polymorphism with susceptibility to type 2 diabetes in Iranian patients.Advanced biomedical research · 2015Article
- Genomic-based tools for the risk assessment, management, and prevention of type 2 diabetes.The application of clinical genetics · 2015Review
- Pharmacogenomics of Drug Response in Type 2 Diabetes: Toward the Definition of Tailored Therapies?PPAR research · 2015Review
- Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors.Pharmacogenomics · 2014Review
- Dipeptidylpeptidase-IV activity and expression reveal decreased damage to the intrahepatic biliary tree in fatty livers submitted to subnormothermic machine-perfusion respect to conventional cold storage.European journal of histochemistry : EJH · 2014Article
- Divergent compensatory responses to high-fat diet between C57BL6/J and C57BLKS/J inbred mouse strains.American journal of physiology. Endocrinology and metabolism · 2013Article
- The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs.Clinical pharmacokinetics · 2013Review
- MicroRNAs as pharmacological targets in diabetes.Pharmacological research · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
A variety of treatment modalities exist for individuals with type 2 diabetes mellitus (T2D). In addition to dietary and physical activity interventions, T2D is also treated pharmacologically with nine major classes of approved drugs. These medications include insulin and its analogues, sulfonylureas, biguanides, thiazolidinediones (TZDs), meglitinides, α-glucosidase inhibitors, amylin analogues, incretin hormone mimetics, and dipeptidyl peptidase 4 (DPP4) inhibitors. Pharmacological treatment strategies for T2D are typically based on efficacy, yet favorable responses to such therapeutics are oftentimes variable and difficult to predict. Characterization of drug response is expected to substantially enhance our ability to provide patients with the most effective treatment strategy given their individual backgrounds, yet pharmacogenetic study of diabetes medications is still in its infancy. To date, major pharmacogenetic studies have focused on response to sulfonylureas, biguanides, and TZDs. Here, we provide a comprehensive review of pharmacogenetics investigations of these specific anti-diabetes medications. We focus not only on the results of these studies, but also on how experimental design, study sample issues, and definition of 'response' can significantly impact our interpretation of findings. Understanding the pharmacogenetics of anti-diabetes medications will provide critical baseline information for the development and implementation of genetic screening into therapeutic decision making, and lay the foundation for "individualized medicine" for patients with T2D.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.